One In, One Out: Mirum Seeks New EU Indication For Maralixibat, Withdraws Another
Kyowa Kirin And Sanofi Want CHMP To Re-Examine Earlier Opinion About Their Products
Companies Can Withdraw Their Marketing Applications At Any Stage Of The EMA Review • Source: Alamy 
